





How to Maximize the Effectiveness of ARICEPT




Clinical features of AD



Symptom Progression in AD




Effect of Cholinesterase Inhibitors



Effect of Short-Term Treatment



FIGURE 1. Change from baseline in the ADAS-Cog



Effect of long-Term Treatment




2-year data			
Doody et al. (19)	Donepezil (5–10 mg/day)	Open-label continuation of two placebo-controlled studies, total duration 144 weeks (<i>n</i> = 763)	ADAS-cog: declined by 10–12 points over 144 weeks
Grossberg et al. (10)	Rivastigmine (2–12 mg/day)	Meta-analysis of two open-label continuations of four placebo-controlled studies, total duration 104 weeks (<i>n</i> = 2010)	ADAS-cog: declined by 4–5 points less than predicted, had patients been left 'untreated'
3-year data			
Klatte et al. (20)	Donepezil (5–10 mg/day) and vitamin E (1000 U/day)	Retrospective review of 130 patients over 3 years, compared with historical untreated patients	MMSE: 6.3-point decline over 3 years, compared with 9.1-point decline in the historical patients, indicating a slower cognitive decline in patients receiving donepezil and vitamin E
Raskind et al. (27)	Galantamine (24 mg/day)	Open-label continuation of two placebo-controlled studies, maximum total duration 36 months (<i>n</i> = 194)	ADAS-cog: mean change of 10.2 points compared with baseline (month 0); 50% less than that predicted for 'untreated' patients
4-year data			
Burns et al. (28)	Galantamine (24 mg/day)	Open-label continuation of two placebo-controlled studies, maximum total duration 48 months	ADAS-cog: mean annual decline approximately 50% less than that predicted for 'untreated' patients
5-year data			
Small et al. and Sano et al. (12,13)	Rivastigmine (2–12 mg/day)	Meta-analysis of two open-label continuations of four placebo-controlled studies, maximum total duration 260 weeks (<i>n</i> = 2010)	ADAS-cog: mean annual decline of 3.9 points; patients remaining on rivastigmine for 5 years declined by about 20 points less than predicted for model-based 'untreated' patients MMSE: mean annual decline of 1.7 points; patients remaining on rivastigmine for 5 years declined by 7 points less than predicted for model-based 'untreated' patients
Rogers et al. (24)	Donepezil (5–10 mg/day)	Open-label continuation of a placebo-controlled study, maximum total duration 254 weeks (<i>n</i> = 133)	ADAS-cog: mean annual decline of at least 6 points; similar to expected placebo decline of 7 points per year

ARICEPT for slow progression of AD



ARICEPT Treatment





Primary Prevention
Identification of High-Risk
Individuals
Prevention of progression

Secondary Prevention
Early Identification
Early tx

Treatment
Minimize Disability
Treat Symptoms

Normal

Pre-Symptomatic
AD

Mild
Cognitive
Impairment

Alzheimer
Disease

*No Pathology,
No Symptoms*

*Early Pathology,
No Symptoms*

*AD Pathology,
Amnesia*

*Extreme Pathology,
Cognitive Impairment*

Disease Progression






Working Criteria for Mild Cognitive Impairment

- Subjective memory complaint and objective memory deficit (ie, delayed recall >1.5 SD below age and education norms)
- Preserved general cognitive ability (Mini-Mental State Examination [MMSE] ≥ 24)
- Intact activities of daily living (ADL)
- Not demented (Clinical Dementia Rating [CDR] 0.5)
- MCI may be regarded as incipient or prodromal Alzheimer's disease (AD)
- Patients with MCI progress to AD at a higher annual rate (10% to 15%) than normal elderly patients (1% to 2%)


Survival curve of persons characterized as having a mild cognitive impairment for 6 years



Progression of MCI to AD



- **10-15 % per year** by Petersen
- **26 % over two year** by Nordberg
- **50 % conversion to AD within 3-4 year** by Hanninen



ARICEPT for Mild Cognitive Impairment



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812


JUNE 9, 2005

VOL. 352 NO. 23


Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment

- *Design*: 3 years, randomized, multicenter, randomized, double-blind, placebo-controlled, parallel study
(→ *Open-label donepezil after conversion to AD*)

ARICEPT delays conversion to dementia



Result of Early AD study (1)




***Improvement ≥ 4 points : 16% placebo, 37% donepezil**

***Improvement ≥ 7 points : 7% placebo, 10% donepezil**

Result of Early AD study (2)



MMSE



* Improvements from week 6 ($P=.02$) through week 24 ($P=.03$)

* Difference 1.8 points ($P = .002$) at the end point


Effect of Early and continuous ARICEPT



3-Year Study of Donepezil Therapy in Alzheimer's Disease: Effects of Early and Continuous Therapy

B. Winblad^a A. Wimo^b K. Engedal^c H. Soininen^d F. Verhey^e
G. Waldemar^f A.-L. Wetterholm^g A. Haglund^g R. Zhang^h R. Schindler^h
for the Donepezil Nordic Study Group

Benefit of early and persistent treatment






Efficacy of ARICEPT for DNHP

Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease


David S. Geldmacher, MD,^{*†} George Provenzano, PhD,[‡] Thomas McRae, MD,[§]
Vera Mastey, MS,^{||} and John R. Ieni, PhD[¶]





ARICEPT delayed 2 year to NHP

Median time to first dementia-related nursing home placement



Keep patients in the community for more than 5 years



Long-term efficacy of ARICEPT



ELSEVIER

European Neuropsychopharmacology 10 (2000) 195–203

EUROPEAN NEURO-
PSYCHOPHARMACOLOGY

www.elsevier.com/locate/euroneuro

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

S.L. Rogers^{a,*}, R.S. Doody^b, R.D. Pratt^c, J.R. Ieni^c

- Design: for up to cumulative 254 weeks (4.9 years)




Result of long-term efficacy of ARICEPT



ADAS-cog

→ over 254 cumulative weeks



Galantamine for AD and MCI



- Preliminary results of two 2-year, randomized, placebo-controlled trials of galantamine in a total of 2048 patients indicated **no significant differences in the rate of progression from MCI to AD**



Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEX study

Howard H Feldman, Steven Ferris, Bengt Winblad, Nikolaos Sfikas, Linda Mancione, Yunsheng He, Sibel Tekin, Alistair Burns, Jeffrey Cummings, Teodoro del Ser, Domenico Inzitari, Jean-Marc Orgogozo, Heinrich Sauer, Philip Scheltens, Elio Scarpini, Nathan Herrmann, Martin Farlow, Steven Potkin, H Cecil Charles, Nick C Fox, Roger Lane

Summary

Objective To assess the effect of rivastigmine in patients with mild cognitive impairment (MCI) on the time to clinical diagnosis of Alzheimer's disease (AD) and the rate of cognitive decline.

Methods The study was a double-blind, randomised, placebo-controlled trial of up to 48 months. All patients had MCI operationally defined by having cognitive symptoms, a global clinical dementia rating stage of 0·5, a score of less than 9 on the New York University delayed paragraph recall test, and by not meeting the diagnostic criteria for AD. Primary efficacy variables were time to clinical diagnosis of AD, and change in performance on a cognitive test battery. This study is registered with the US National Institutes of Health clinical trials database (ClinicalTrials.gov), number NCT00000174.

Findings Of 1018 study patients enrolled, 508 were randomly assigned to rivastigmine and 510 to placebo; 17·3% of patients on rivastigmine and 21·4% on placebo progressed to AD (hazard ratio 0·85 [95% CI 0·64–1·12]; $p=0\cdot225$). There was no significant difference between the rivastigmine and placebo groups on the standardised Z score for the cognitive test battery measured as mean change from baseline to endpoint ($-0\cdot10$ [95% CI $-0\cdot63$ to $0\cdot44$], $p=0\cdot726$). Serious adverse events were reported by 141 (27·9%) rivastigmine-treated patients and 155 (30·5%) patients on placebo; adverse events of all types were reported by 483 (95·6%) rivastigmine-treated patients and 472 (92·7%) placebo-treated patients. The predominant adverse events were cholinergic: the frequencies of nausea, vomiting, diarrhoea, and dizziness were two to four times higher in the rivastigmine group than in the placebo group.

Interpretation There was no significant benefit of rivastigmine on the progression rate to AD or on cognitive function over 4 years. The overall rate of progression from MCI to AD in this randomised clinical trial was much lower than predicted. Rivastigmine treatment was not associated with any significant safety concerns.

Lancet Neurol 2007; 6: 501–12

Published Online

May 3, 2007

DOI:10.1016/S1474-4422(07)70109-6

See [Reflection and Reaction](#) page 473

See [In Context](#) page 482

Division of Neurology, University of British Columbia Hospital, Vancouver, Canada (H H Feldman MD); Alzheimer's Disease Center, New York University School of Medicine, New York, USA (S Ferris PhD); Karolinska Institute Alzheimer Disease Research Centre, Karolinska University Hospital, Huddinge, Sweden (B Winblad MD); Novartis Pharma AG, Basel, Switzerland (N Sfikas PhD); Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (L Mancione BA, S Tekin MD, R Lane MD); Clinical Pharmacogenetics, Novartis Pharmaceuticals Corporation